Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.

Alberto Zambelli,Edda Simoncini,Monica Giordano,Nicla Laverde,Gabriella Farina,Valter Torri,Giorgio Colombo, Giulia Piacentini,Vittoria Fotia,Lucia Vassalli,Palma Pugliese,Paola Poletti,Elena Rota Caremoli,Carlo Tondini

The Breast（2020）

引用 8|浏览24

暂无评分

摘要

•The 21-gene assay is validated to guide adjuvant treatment decisions in eBC.•We identify patients in which 21-gene testing led to best performance in CT sparing.•Testing this patient group obtains the best performance in cost-benefit-ratio.•Lombardy approves the 21-gene assay for patients at clinical intermediar risk.

查看译文

关键词

Decision impact,Early breast cancer,21-gene assay,Oncotype DX,Recurrence Score,Adjuvant chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要